GLC Medical

GLC Medical is a Canadian diagnostics and medical technology company developing rapid point-of-care pathogen detection tools. Its core asset is the GLCM Biosensor Platform, which uses electrical impedance spectroscopy together with cloud-based analytics and artificial intelligence-enabled software to deliver rapid test results without complex instrumentation. The company has highlighted SARS-CoV-2 as its first product vertical and has described broader plans to adapt the platform for multiple pathogens and multiplex testing. GLC Medical appears to be focused on commercialization partnerships, validation activities, and geographic expansion rather than an advanced therapeutic pipeline. The business is healthcare-related, but it is primarily a diagnostics platform company rather than a therapeutics developer.